Using Cannabis Compounds to Treat Inflammatory Bowel Disease: Where the Science Stands
Cannabis compounds show promise for relieving IBD symptoms like pain, diarrhea, and appetite loss, but clinical evidence proving efficacy and safety remains insufficient.
Quick Facts
What This Study Found
Fifty years after THC was identified, this expert review assessed the clinical translation of cannabinoids for inflammatory bowel diseases (IBD) including Crohn's disease and ulcerative colitis.
Surveys and small clinical studies confirmed that IBD patients frequently use cannabis to manage diarrhea, abdominal pain, and appetite loss. Both plant-derived cannabinoids (THC and CBD) and synthetic versions (dronabinol, nabilone) showed potential for symptom relief in experimental models.
However, the reviewers concluded there is still insufficient clinical evidence to prove efficacy, tolerability, and safety of cannabinoid-based medications for IBD patients, leaving clinicians without evidence-based guidelines for recommending these treatments.
Key Numbers
Synthetic cannabinoids dronabinol and nabilone are already available by prescription. The review covers 50 years of cannabinoid research since THC's discovery.
How They Did This
The researchers reviewed recent data on cannabis and cannabinoid effects in experimental IBD models and clinical trials with IBD patients using a PubMed database search. They also provided background on the endocannabinoid system and its relevance to gastrointestinal inflammation.
Why This Research Matters
IBD affects millions worldwide and many patients self-medicate with cannabis despite limited clinical evidence. This review identifies a significant gap between patient behavior and medical evidence, highlighting the urgent need for rigorous clinical trials.
The Bigger Picture
The endocannabinoid system plays a documented role in gut inflammation and motility, providing biological plausibility for cannabinoid therapy in IBD. But biological plausibility alone does not equal clinical proof, and this review makes clear that the field has not yet bridged that gap.
What This Study Doesn't Tell Us
This is a narrative expert commentary rather than a systematic review with formal quality assessment. Most evidence comes from preclinical models and small clinical studies, with very few randomized controlled trials available for analysis.
Questions This Raises
- ?Could CBD-dominant preparations offer anti-inflammatory benefits without THC side effects for IBD patients?
- ?What dosing protocols would be needed for clinical trials?
- ?Could cannabinoids complement existing IBD therapies rather than replace them?
Trust & Context
- Key Stat:
- Clinical evidence proving cannabinoid safety and efficacy for IBD remains insufficient
- Evidence Grade:
- Expert narrative review drawing on experimental and clinical data, rated moderate because it synthesizes meaningful evidence but lacks systematic methodology.
- Study Age:
- Published in 2017, covering cannabinoid-IBD research through early 2017.
- Original Title:
- Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?
- Published In:
- Expert review of gastroenterology & hepatology, 11(4), 329-337 (2017)
- Authors:
- Hasenoehrl, Carina(2), Storr, Martin(5), Schicho, Rudolf(3)
- Database ID:
- RTHC-01395
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
Can cannabis treat Crohn's disease or ulcerative colitis?
Small studies and patient surveys suggest cannabis can relieve symptoms like pain, diarrhea, and appetite loss, but there is not yet enough clinical evidence to establish it as a proven treatment for either condition.
Are there approved cannabinoid medications for IBD?
While synthetic cannabinoids like dronabinol and nabilone are available by prescription for other conditions, none are specifically approved for IBD. Clinical trials are needed before cannabinoid therapies can be recommended for bowel diseases.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- cannabis-and-arthritis-research
Cite This Study
https://rethinkthc.com/research/RTHC-01395APA
Hasenoehrl, Carina; Storr, Martin; Schicho, Rudolf. (2017). Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?. Expert review of gastroenterology & hepatology, 11(4), 329-337. https://doi.org/10.1080/17474124.2017.1292851
MLA
Hasenoehrl, Carina, et al. "Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?." Expert review of gastroenterology & hepatology, 2017. https://doi.org/10.1080/17474124.2017.1292851
RethinkTHC
RethinkTHC Research Database. "Cannabinoids for treating inflammatory bowel diseases: where..." RTHC-01395. Retrieved from https://rethinkthc.com/research/hasenoehrl-2017-cannabinoids-for-treating-inflammatory
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.